Table 2.

PIK3CA mutation or copy number gain in lung cancer cell lines and tumors

SamplesNo. samples with the following factor in PIK3CA
MutationsCopy number gainBoth mutations and gainEither mutations or gain
NSCLC cell lines (n = 86)4 (4.7%)8 (9.3%)1 (1.2%)11 (12.8%)
    Squamous cell lines (n = 14)1 (7.1%)5 (35.7%)1 (7.1%)5 (35.7%)
    Adenocarcinoma cell lines (n = 51)1 (2.0%)3 (5.9%)0 (0%)4 (7.8%)
    Other NSCLC cell lines (n = 21)2 (9.5%)0 (0%)0 (0%)2 (9.5%)
NSCLC tumors (n = 356)11 (3.1%) *61 (17.1%)4 (1.1%)68 (19.1%)
    Squamous cell tumors (n = 139)5 (3.6%)46 (33.1%)3 (2.2%)48 (34.5%)
    Adenocarcinomas (n = 195)5 (2.6%)12 (6.2%)0 (0%)17 (8.7%)
    Other NSCLC tumors (n = 22)1 (4.5%)3 (13.6%)1 (4.5%)3 (13.6%)
SCLC cell lines (n = 43)0 (0%)2 (4.7%)0 (0%)2 (4.7%)
ExPuSC cell lines (n = 3)2 (66.7%)0 (0%)0 (0%)2 (66.7%)
  • * PIK3CA mutations were detected in 11 of 691 NSCLC tumors (1.6%), as shown in Table 1. However, as only 356 of 691 tumors were analyzed for both mutations and gene copy number of PIK3CA (all 11 mutant tumors were represented in this subset), the frequency of mutations in this subset increased to 3.1%.